Mengqi Shi

554 citations
10 papers · 417 indexed · h-index 7
Topics
Radiopharmaceutical Chemistry and Applications (5 papers)Peptidase Inhibition and Analysis (3 papers)Medical Imaging Techniques and Applications (2 papers)
Partner nations
ChinaSingaporeGermany

In The Last Decade

Mengqi Shi

10 papers receiving 411 citations

Peers

Mengqi Shi
Comparison fields: 5 of 46
  • Oncology 250
  • Molecular Biology 128
  • Pulmonary and Respiratory Medicine 121
  • Radiology, Nuclear Medicine and Imaging 107
  • Cancer Research 104
Replace Muhsin H. Younis with:
Muhsin H. Younis United States
Yvonne H. W. Derks Netherlands
Anne‐Sophie Wozny France
Tatsuya Shimomura Japan
Carlo Fremd Germany
C R Divgi United States
Hiroyuki Tao Japan
Tamahiro Nishihara Japan
Mengqi Shi relative to Muhsin H. Younis United States Muhsin H. Younis's profile →
Citations per field
00.5×10×20×30×37×
Muhsin H. Younis · 1×
Citations per year

Countries citing papers authored by Mengqi Shi

Since Specialization
Citations

This map shows the geographic impact of Mengqi Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengqi Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengqi Shi more than expected).

Fields of papers citing papers by Mengqi Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengqi Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengqi Shi. The network helps show where Mengqi Shi may publish in the future.

Co-authorship network of co-authors of Mengqi Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Mengqi Shi. A scholar is included among the top collaborators of Mengqi Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengqi Shi. Mengqi Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
#WorkIndexed citations
1 1
2 2
3 11
4 6
5 66
6 33
7 2
8 10
9 100
10 186

About Mengqi Shi

Mengqi Shi is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology and Allergy, having authored 10 papers that have together received 417 indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (5 papers), Peptidase Inhibition and Analysis (3 papers) and Medical Imaging Techniques and Applications (2 papers). The work is most often cited by research in Oncology (250 citations), Cancer Research (104 citations) and Radiology, Nuclear Medicine and Imaging (107 citations). Mengqi Shi has collaborated with scholars based in China, Singapore and Germany. Frequent co-authors include Xinhai Zhang, Boxin Zhang, Xiaoyuan Chen, Peng‐Fei Xu, Xinying Zeng, Zhide Guo, Xuejun Wen, Pek‐Lan Khong, Xianzhong Zhang and Jingchao Li. Their work appears in journals such as Biomacromolecules, Theranostics and European Journal of Nuclear Medicine and Molecular Imaging.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026